UCB dedicates Georgia site. UCB stock sits 30.78 percent below its high

Published on 10/14/2026 at 11:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A Georgia site was dedicated on October 10, 2026. UCB stock costs EUR 200.40 on October 14, 2026, 30.78 percent below its EUR 289.50 high.

Georgia site and growth milestones

UCB dedicated a Georgia biologics campus site on October 10, 2026.
First-half 2026 revenue reached EUR 4.27 billion, up 22.00 percent year over year.
UCB stock trades at EUR 200.40 at 11:34 a.m. CEST at Lang & Schwarz on October 14, 2026, 30.78 percent below its 52-week high.

Architektur-Render eines geschwungenen Glasgebäudes mit Reflexionsbecken und begrünter Umgebung — UCB S.A. (BE0003739530) symbolisiert durch elegantes Architektur-Render eines modernen Biopharma-Hauptsitzes mit Glasfassade, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) was trading at EUR 200.40 at Lang & Schwarz on October 14, 2026 at 11:34 a.m. CEST, 30.78 percent below its EUR 289.50 52-week high. The biopharmaceutical company dedicated the future site of a biologics manufacturing campus in Gwinnett County, Georgia, on October 10, 2026, as Yahoo Finance reported.

Three milestones shape the story

UCB's recent operating picture combines commercial growth with a larger manufacturing footprint. On September 23, 2026, Quartr summarized first-half 2026 revenue growth of 22.00 percent to EUR 4.27 billion, alongside a 68.00 percent increase in EBITDA and upgraded guidance.

On September 30, 2026, Dermatology Times reported UCB data showing that 47.40 percent of patients with the shortest diagnosis duration achieved IHS4-100 at three years, compared with 33.30 percent among patients with the longest duration. The figures relate to post hoc analyses of the BE HEARD program for BIMZELX.

What does the pipeline mean for growth?

The commercial case rests heavily on products already gaining scale. UCB's investor materials list BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak sales guidance above EUR 7.00 billion, while FINTEPLA sales reached EUR 239.00 million in the same period, according to UCB.

The pipeline also supplies dated milestones. UCB's investor materials list topline results for STACCATO alprazolam in the fourth quarter of 2026 or first half of 2027, while several other programs have first-half 2027 readouts or starts.

Stock stays below yearly high

At EUR 200.40, the Lang & Schwarz quote on October 14, 2026 at 11:34 a.m. CEST placed UCB stock 30.78 percent below the EUR 289.50 52-week high. The valuation context leaves commercial execution and clinical milestones as the concrete measures for assessing whether the growth pipeline can narrow that gap.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.